TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07633470: A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

Sponsor: Alpha Cognition, Inc · Phase: PHASE4 · Area: CNS_NEUROLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,390,080

Rescue Site Savings

+$1,583,040

Unlock Full NCT07633470 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07633470 Rescue Dossier →